Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 1, 2011, Pages 177-184

  Kim, Jung A ^a,b   Lee, Jeeyun ^a   Han, Boram ^a   Park, Se Hoon ^a   Park, Joon Oh ^a   Park, Young Suk ^a   Lim, Ho Yeong ^a   Kang, Won Ki ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Advanced gastric cancer; Docetaxel; DP; FOLFIRI

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 79959605085     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1452-4     Document Type: Article

References (21)

1. National Cancer Information Center, available online at http://www.cancer.go.kr/cms/statics/incidence/index.html (Accessed 11 Sept 2009)
2. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E (2005) Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23:5660-5667
3. Bouche O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsene D, Paitel JF, Guerin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C (2004) Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803. J Clin Oncol 22:4319-4328 (Pubitemid 41199650)
4. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M, Fayers P (1999) Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical co-operative group. Br J Cancer 79:1522-1530 (Pubitemid 29116815)
5. Kim H, Park JH, Bang SJ, Kim DH, Cho HR, Kim GY, Min YJ (2005) A phase II study of docetaxel and cisplatin in patients with gastric cancer recurring after or progressing during 5-FU/platinum treatment. Jpn J Clin Oncol 35:727-732 (Pubitemid 43091657)
6. Kim SG, Oh SY, Kwon HC, Lee S, Kim JH, Kim SH, Kim HJ (2007) A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer. Jpn J Clin Oncol 37:744-749 (Pubitemid 350123351)
7. Kim SH, Lee GW, Il Go S, Cho SH, Kim HJ, Kim HG, Kang JH (2010) A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen. Am J Clin Oncol. doi:10.1097/COC.0b013e3181bead7b
8. Kim ST, Kang WK, Kang JH, Park KW, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Im YH, Park K (2005) Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer. Br J Cancer 92:1850-1854 (Pubitemid 40826132)
9. Lorizzo K, Fazio N, Radice D, Boselli S, Ariu L, Zampino MG, Nole F, Magni E, Ardito R, Minchella I, Rocca A, Di Meglio G, Squadroni M, de Braud F (2009) Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer. Cancer Chemother Pharmacol 64:301-306
10. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S (2003) Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan clinical oncology group study (JCOG9205). J Clin Oncol 21:54-59
11. Ozdemir NY, Abali H, Oksuzoglu B, Budakoglu B, Uncu D, Guler T, Odabasi H, Zengin N (2009) The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. Med Oncol
12. Park KW, Ahn JS, Park YS, Lee J, Kang JH, Park JO, Lim HY, Im YH, Kang WK, Park K, Lee SI (2007) Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer. Cancer Chemother Pharmacol 59:17-21 (Pubitemid 44796098)
13. Park SH, Kang WK, Lee HR, Park J, Lee KE, Lee SH, Park JO, Kim K, Kim WS, Chung CW, Im YH, Lee MH, Park CH, Park K (2004) Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen. Am J Clin Oncol 27:477-480 (Pubitemid 39371942)
14. Park SH, Nam E, Park J, Cho EK, Shin DB, Lee JH, Lee WK, Chung M, Lee SI (2008) Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer. Ann Oncol 19:729-733 (Pubitemid 351461044)
15. Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Koberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F (2007) Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the swiss group for clinical cancer research. J Clin Oncol 25:3217-3223 (Pubitemid 47325604)
16. Seo MD, Lee KW, Lim JH, Yi HG, Kim DY, Oh DY, Kim JH, Im SA, Kim TY, Lee JS, Bang YJ (2008) Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer. Jpn J Clin Oncol 38:589-595
17. Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Lee SS, Lee JS, Kang YK (2008) Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane. Am J Clin Oncol 31:151-156 (Pubitemid 351522729)
18. Tomasello G, Chiesa MD, Buti S, Brighenti M, Negri F, Rovere RK, Martinotti M, Buononato M, Brunelli A, Lazzarelli S, Donati G, Passalacqua R (2010) Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen. Tumori 96:48-53
19. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991-4997 (Pubitemid 46631401)
20. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903-2909 (Pubitemid 46630593)
21. Yun J, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK (2010) A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer. Eur J Cancer 46:885-891